Meet VAR2 Pharmaceuticals at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

On November 17, 2026 VAR2 Pharmaceuticals reported that it is attending the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona between 18-20 November 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our Executive Chairman of the Board Mads Daugaard will be accompanied by our Deputy Chief Medical Officer Thomas Clausen at the event. VAR2 Pharmaceuticals will feature a Late-breaking Poster Presentation (poster no. PB-011, abstract no. 26LBA) reporting on the results from our just completed Phase 0 Nuclear Imaging Basket Trial VARTUTRACE (NCT06645808).

We are looking forward to meeting old and new colleagues, and discussing potential synergies with our lead ADC program planned to start a Phase 1 in Q2 2027.

(Press release, Var2 Pharmaceuticals, NOV 17, 2026, View Source [SID1234674884])